In Switzerland, RTX is licensed to treat severe RA if combined with methotrexate (MTX) after at least one TNF inhibitor failure and, since 2014, to treat severe AAV when cyclophosphamide fails or is contraindicated. Here, TNF is linked to rheumatoid arthritis.